Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays.

Budna-Tukan J, Świerczewska M, Mazel M, Cieślikowski WA, Ida A, Jankowiak A, Antczak A, Nowicki M, Pantel K, Azria D, Zabel M, Alix-Panabières C.

Cancers (Basel). 2019 Jun 10;11(6). pii: E802. doi: 10.3390/cancers11060802.

2.

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F.

Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13.

PMID:
30811063
3.

ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.

Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M, Mazel M, Cayrefourcq L, Geraci S, Vacher S, Pantano F, Filipits M, Driouch K, Bieche I, Gnant M, Jacot W, Aubin JE, Duterque-Coquillaud M, Alix-Panabières C, Clézardin P, Bonnelye E.

Oncogene. 2019 Feb;38(7):950-964. doi: 10.1038/s41388-018-0579-3. Epub 2018 Nov 26.

PMID:
30478447
4.

Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.

Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, Sasaki C, Alix-Panabières C, Lianidou E, Psyrri A.

Ann Oncol. 2017 Aug 1;28(8):1923-1933. doi: 10.1093/annonc/mdx206.

PMID:
28838214
5.

EpCAM-Independent Enrichment and Detection of Viable Circulating Tumor Cells Using the EPISPOT Assay.

Soler A, Cayrefourcq L, Mazel M, Alix-Panabières C.

Methods Mol Biol. 2017;1634:263-276. doi: 10.1007/978-1-4939-7144-2_22.

PMID:
28819858
6.

Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.

Kuske A, Gorges TM, Tennstedt P, Tiebel AK, Pompe R, Preißer F, Prues S, Mazel M, Markou A, Lianidou E, Peine S, Alix-Panabières C, Riethdorf S, Beyer B, Schlomm T, Pantel K.

Sci Rep. 2016 Dec 21;6:39736. doi: 10.1038/srep39736.

7.

Frequent expression of PD-L1 on circulating breast cancer cells.

Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabières C.

Mol Oncol. 2015 Nov;9(9):1773-82. doi: 10.1016/j.molonc.2015.05.009. Epub 2015 Jun 9.

8.

The leguminous species Anthyllis vulneraria as a Zn-hyperaccumulator and eco-Zn catalyst resources.

Grison CM, Mazel M, Sellini A, Escande V, Biton J, Grison C.

Environ Sci Pollut Res Int. 2015 Apr;22(8):5667-76. doi: 10.1007/s11356-014-3605-1. Epub 2014 Sep 25.

PMID:
25253057
9.

HGCS: an online tool for prioritizing disease-causing gene variants by biological distance.

Itan Y, Mazel M, Mazel B, Abhyankar A, Nitschke P, Quintana-Murci L, Boisson-Dupuis S, Boisson B, Abel L, Zhang SY, Casanova JL.

BMC Genomics. 2014 Apr 3;15:256. doi: 10.1186/1471-2164-15-256.

10.

In vivo analysis of Ifn-γ1 and Ifn-γ2 signaling in zebrafish.

Aggad D, Stein C, Sieger D, Mazel M, Boudinot P, Herbomel P, Levraud JP, Lutfalla G, Leptin M.

J Immunol. 2010 Dec 1;185(11):6774-82. doi: 10.4049/jimmunol.1000549. Epub 2010 Nov 3. Erratum in: J Immunol. 2012 Feb 15;188(4):2038.

11.

The two groups of zebrafish virus-induced interferons signal via distinct receptors with specific and shared chains.

Aggad D, Mazel M, Boudinot P, Mogensen KE, Hamming OJ, Hartmann R, Kotenko S, Herbomel P, Lutfalla G, Levraud JP.

J Immunol. 2009 Sep 15;183(6):3924-31. doi: 10.4049/jimmunol.0901495. Epub 2009 Aug 28.

12.

Induction of antigen-specific CTL responses using antigens conjugated to short peptide vectors.

Day FH, Zhang Y, Clair P, Grabstein KH, Mazel M, Rees AR, Kaczorek M, Temsamani J.

J Immunol. 2003 Feb 1;170(3):1498-503.

13.

Leptospiral proteins recognized during the humoral immune response to leptospirosis in humans.

Guerreiro H, Croda J, Flannery B, Mazel M, Matsunaga J, Galvão Reis M, Levett PN, Ko AI, Haake DA.

Infect Immun. 2001 Aug;69(8):4958-68.

14.

Doxorubicin-peptide conjugates overcome multidrug resistance.

Mazel M, Clair P, Rousselle C, Vidal P, Scherrmann JM, Mathieu D, Temsamani J.

Anticancer Drugs. 2001 Feb;12(2):107-16.

PMID:
11261883
15.

Physico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-binding affinity.

Drin G, Mazel M, Clair P, Mathieu D, Kaczorek M, Temsamani J.

Eur J Biochem. 2001 Mar;268(5):1304-14.

16.

The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection.

Haake DA, Chao G, Zuerner RL, Barnett JK, Barnett D, Mazel M, Matsunaga J, Levett PN, Bolin CA.

Infect Immun. 2000 Apr;68(4):2276-85.

17.

Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection.

Haake DA, Mazel MK, McCoy AM, Milward F, Chao G, Matsunaga J, Wagar EA.

Infect Immun. 1999 Dec;67(12):6572-82.

18.

Characterization of leptospiral outer membrane lipoprotein LipL36: downregulation associated with late-log-phase growth and mammalian infection.

Haake DA, Martinich C, Summers TA, Shang ES, Pruetz JD, McCoy AM, Mazel MK, Bolin CA.

Infect Immun. 1998 Apr;66(4):1579-87.

19.

Characterization of the cDNA and pattern of expression of a new gene over-expressed in human hepatomas and colonic tumors.

Charrasse S, Mazel M, Taviaux S, Berta P, Chow T, Larroque C.

Eur J Biochem. 1995 Dec 1;234(2):406-13.

20.

The controlled delivery of thiopental and delayed cerebral revascularization.

Yonas H, Dujovny M, Nelson D, Lipton SD, Segel R, Agdeppa D, Mazel M.

Surg Neurol. 1981 Jan;15(1):27-34.

PMID:
7256521
21.

Obstructive vascular disease treated by urokinase.

Mazel MS, Riera R.

Med Trial Tech Q. 1979 Winter;25(3):319-31. No abstract available.

PMID:
423742
22.

Report on the use of urokinase in acute myocardial infarction.

Mazel MS.

Vasc Surg. 1976 Jan-Feb;10(1):46-52. No abstract available.

PMID:
961035
23.

The use of urokinase in acute myocardial infarction: report of two cases.

Mazel MS, Parsa F, Riera R.

J Am Geriatr Soc. 1975 Sep;23(9):419-25.

PMID:
1151039
24.

A new "wonder" drug to dissolve clots. The results of urokinase therapy in acute myocardial infarction, pulmonary embolism and deep vein thrombosis.

Mazel MS, Riera R, Levine ER.

Med Trial Tech Q. 1975 Summer;22(1):52-67. No abstract available.

PMID:
1165704
25.

A surgeon reviews a half century of progress in the treatment of coronary heart disease.

Mazel MS.

J Am Geriatr Soc. 1973 Aug;21(8):355-61. No abstract available.

PMID:
4578575
26.

Revascularization of the myocardium: a simple procedure--a 15-year study.

Mazel MS, Riera R, Canete D.

Vasc Surg. 1967 Dec;1(4):191-201. No abstract available.

PMID:
5583452
27.

Clot lysis with fibrinolysin: progress report.

Mazel MS, Riera R, Stern JR.

J Am Geriatr Soc. 1967 Jan;15(1):87-94. No abstract available.

PMID:
4224586
29.

ROLE OF THE NURSE AND NURSES' AIDE IN TREATMENT OF CARDIAC EMERGENCY.

MAZEL MS, RIERA R.

Hosp Top. 1965 May;43:61-2. No abstract available.

PMID:
14282339
30.

PREVENTION OF CARDIAC ARREST.

MAZEL MS, RIERA R.

Hosp Prog. 1965 Apr;46:80-1. No abstract available.

PMID:
14262695
31.

THE RATIONALE OF FIBRINOLYSIN THERAPY.

MAZEL MS, BOLTON HE, RIERA R.

Clin Med (Northfield). 1964 Jul;71:1175-83. No abstract available.

PMID:
15446187
32.

PREVENTION OF CARDIAC ARREST DURING SURGERY.

MAZEL MS, BOLTON HE, TAPIA FA, WU L, RIERA R.

Dis Chest. 1964 Jun;45:639-45. No abstract available.

PMID:
14168532
33.

THE PRODROMAL SIGNS OF CARDIAC ARREST DURING SURGERY.

MAZEL MS, BOLTON HE, TAPIA FA, WU L, CABRAL H, RIERA R.

J Abdom Surg. 1964 May;6:64-7. No abstract available.

PMID:
14159432
34.

THROMBOLYSIN TREATMENT OF PULMONARY EMBOLISM FOLLOWING SURGERY. A REPORT OF TWO CASES.

MAZEL MS, BOLTON HE, RIERA R.

Angiology. 1964 Apr;15:171-3. No abstract available.

PMID:
14158901
35.

EXPERIMENTAL BRAIN PERFUSION WITH HIGH CONCENTRATION OF FIBRINOLYSIN.

BOLTON HE, CABRAL H, RIERA R, MAZEL MS.

Geriatrics. 1964 Mar;19:222-4. No abstract available.

PMID:
14126139
36.

Coronary arterial and other intravascular thromboses treated with fibrinolysin. Experimental and clinical results.

MAZEL MS, BOLTON HE, STERN JR, RIERA R, CABRAL H.

Angiology. 1963 Feb;14:88-92. No abstract available.

PMID:
13934202
37.

Cardiopexy versus endarterectomy in the treatment of ischemic heart disease.

MAZEL MS, BOLTON HE.

Angiology. 1961 Aug;12:335-45. No abstract available.

PMID:
13768646
38.

Primary carcinoma in the area of radical mastectomy seventeen years later.

MAZEL MS, URBAN R.

Ill Med J. 1961 Apr;119:199-201. No abstract available.

PMID:
13768647
39.

Selective coronary cine-arteriography. An improved method for visualization of the coronary arteries.

TAPIA FA, BOLTON HE, MAZEL MS.

Angiology. 1961 Jan;12:46-51. No abstract available.

PMID:
13775250
40.

Evaluation of the bilateral internal mammary artery ligation.

MAZEL MS.

Angiology. 1958 Dec;9(6):353-65. No abstract available.

PMID:
13606424
41.

Combined medical and surgical management of coronary heart disease.

MAZEL MS.

J Am Geriatr Soc. 1958 Sep;6(9):643-56. No abstract available.

PMID:
13575098
42.

[Surgical treatment of coronary insifficiency].

MAZEL MS.

Resen Clin Cient. 1957 Jul-Aug;26(7-8):164-7. Portuguese. No abstract available.

PMID:
13494778
43.
44.

A simple operation for the treatment of chronic coronary artery disease.

MAZEL MS, BERNSTEIN MM, CALLEN IR, SCHNAER IL, WU LT, BONK A.

AMA Arch Surg. 1955 Feb;70(2):309-17. No abstract available.

PMID:
13227751
45.

Dysgerminoma ovarii.

MAZEL MS.

Am J Obstet Gynecol. 1947 Jun;53(6):1036-41. No abstract available.

PMID:
20247858
46.

Regional ileitis; report of an asymptomatic lethal case.

MAZEL MS.

Am J Surg. 1946 Mar;71:412-9. No abstract available.

PMID:
21015435

Supplemental Content

Support Center